BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Medicover Hospitals launches new Transcranial Magnetic Stimulation lab in Mumbai

21 August 2026 | News

To offer evidence-based, non-invasive brain stimulation for selected psychiatric conditions and neurological applications

Medicover Hospitals, Navi Mumbai, has launched its Advanced Transcranial Magnetic Stimulation (TMS) Laboratory, expanding access to non-invasive brain stimulation therapy for patients with selected psychiatric and neurological conditions.

The facility will offer evidence-based TMS protocols for conditions including treatment-resistant depression, obsessive-compulsive disorder (OCD), anxious depression, post-traumatic stress disorder (PTSD), smoking cessation, and migraine, along with selected neurological applications where scientific evidence is evolving.

These include stroke rehabilitation, post-stroke speech and language disorders, neuropathic pain, fibromyalgia, Parkinson’s disease, cerebellar ataxia, Alzheimer’s disease, and tinnitus.

TMS uses controlled magnetic pulses to stimulate specific areas of the brain. The treatment is non-invasive and does not require surgery or general anaesthesia. Depending on the condition and protocol, TMS may be used to influence brain circuits involved in mood regulation, cognition, movement, pain processing, and other neurological functions. Patients undergo a detailed clinical assessment before treatment, and the protocol is selected according to the individual's condition and treatment goals.

The new facility will provide TMS for Major Depressive Disorder, Treatment-Resistant Depression, Obsessive-Compulsive Disorder, Anxious Depression, Post-Traumatic Stress Disorder, smoking cessation, and migraine, along with selected neurological applications such as stroke rehabilitation and post-stroke speech and language difficulties. Other neurological conditions, including neuropathic pain, fibromyalgia, Parkinson’s disease, cerebellar ataxia, Alzheimer’s disease and tinnitus, may be considered for appropriate patients based on clinical assessment and available evidence.